NANOBODY

---

 Nanobody is a heavy chain only, single domain antibody. Compared to conventional antibodies, nanobodies are smaller in size, approximately 1/10 the size of regular antibodies. This reduced size provides several advantages, such as improved tissue permeability, and enhanced antigen accessibility, leading to increased targeting ability. Above all, it’s easy to engineer to target specific antigen due its simple structure.
Shaperon, Inc. has developed an efficient and sensitive in-house screening system that allows for the rapid selection and production of nanobodies within a time-frame of just 9 weeks.  Hudson Therapeutics, Inc. will leverage Shaperon's proprietary nanobody technology to accelerate nanobody pipeline development in the U.S.